-
公开(公告)号:US10676771B2
公开(公告)日:2020-06-09
申请号:US15385340
申请日:2016-12-20
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Brian Agnew , Kyle Gee , Schuyler Corry
IPC: C07K16/00 , C07K14/47 , G01N33/533 , C12P21/00 , A61K47/54 , G01N33/531 , C07K1/13 , G01N33/532 , G01N33/50 , G01N33/58 , G01N33/534
Abstract: The present invention generally relates to methods of functionalizing proteins, particularly antibodies, at oligosaccharide linkages, methods of humanizing antibodies by modifying glycosylation, as well as to novel antibodies linked to modified oligosaccharides. The invention further relates to kits that may be used to produce the antibodies of the invention.
-
公开(公告)号:US09645140B2
公开(公告)日:2017-05-09
申请号:US14330727
申请日:2014-07-14
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Brian Agnew , Kyle Gee , Tamara Nyberg
IPC: G01N33/533 , G01N33/532 , G01N33/58 , C12P21/00 , A61K47/48 , G01N33/531 , G01N33/50 , C07K16/00 , G01N33/534
CPC classification number: C12P21/005 , A61K47/549 , A61K47/61 , C07K1/13 , C07K14/47 , C07K16/00 , C07K2317/14 , C07K2317/24 , C07K2317/41 , C12Y302/01096 , G01N33/5005 , G01N33/5008 , G01N33/531 , G01N33/532 , G01N33/533 , G01N33/534 , G01N33/581 , G01N33/582 , G01N33/583 , Y10T436/17
Abstract: Provided in certain embodiments are new methods for forming azido modified biomolecule conjugates of reporter molecules, carrier molecules or solid support. In other embodiments are provided methods for enzymatically labeling a biomolecules with an azide group.
-
公开(公告)号:US20150374723A1
公开(公告)日:2015-12-31
申请号:US14831220
申请日:2015-08-20
Inventor: Brian Agnew , David Graham , Upinder Singh , Scott Grecian
IPC: A61K31/655 , A61K38/21 , A61K31/7088 , A61K45/06
CPC classification number: A61K31/655 , A61K31/7024 , A61K31/7088 , A61K38/212 , A61K38/215 , A61K45/06 , A61K2300/00
Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
Abstract translation: 提供了使用叠氮化物修饰的生物分子如脂肪酸,碳水化合物和脂质来治疗植物,昆虫或感染病毒的动物或抑制病毒如人类免疫缺陷病毒的感染性的方法。 还提供了用叠氮化物修饰的生物分子如脂肪酸,碳水化合物或类异戊二烯脂质来标记病毒(例如人类免疫缺陷病毒)的方法。 此外,提供了利用叠氮化物修饰的生物分子如脂肪酸,碳水化合物或类异戊二烯脂质体内追踪病毒的方法。 叠氮化物修饰的生物分子可以与药学上可接受的赋形剂组合以产生药物组合物,任选地含有另一种抗病毒剂和/或递送剂,例如脂质体。
-
公开(公告)号:US20240392041A1
公开(公告)日:2024-11-28
申请号:US18772605
申请日:2024-07-15
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Brian Agnew , Robert Aggeler , Rolando Brawer
IPC: C07K16/46 , A61K9/00 , A61K47/60 , A61K47/68 , A61K47/69 , C12N9/24 , C12N15/113 , C12P21/00 , G01N33/68
Abstract: Methods are provided for making bispecific antibodies and antibody conjugates comprising site-specifically cross-linking two or more antibodies, antibody fragments or Fc-fusion proteins. Also provided are compositions and uses for the bispecific antibodies and antibody conjugates. The bispecific antibodies may be used to treat a disease or condition. Also provided are methods for site-specifically conjugating a liposome, an mRNA or an siRNA to an antibody, and uses of the antibody-conjugated liposome, mRNA or siRNA.
-
公开(公告)号:US20180092932A1
公开(公告)日:2018-04-05
申请号:US15834639
申请日:2017-12-07
Inventor: Brian Agnew , David Graham , Upinder Singh , Scott Grecian
IPC: A61K31/655 , A61K31/7024 , A61K45/06 , A61K38/21 , A61K31/7088
CPC classification number: A61K31/655 , A61K31/7024 , A61K31/7088 , A61K38/212 , A61K38/215 , A61K45/06 , A61K2300/00
Abstract: Methods of using azide-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to inhibit infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. Also, provided are methods of tracking a virus in vivo, with an azide-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The azide-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
公开(公告)号:US20170137866A1
公开(公告)日:2017-05-18
申请号:US15332304
申请日:2016-10-24
Inventor: Kyle R. Gee , Brian Agnew , Adrian Salic , Timothy J. Mitchison
IPC: C12Q1/68
Abstract: The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. Certain methods are provided that include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Other methods are provided that include a Staudinger ligation between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent comprising a substituted triarylphosphine attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures.
-
公开(公告)号:US20150017703A1
公开(公告)日:2015-01-15
申请号:US14374345
申请日:2013-01-25
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Brian Agnew
IPC: C12N7/00
CPC classification number: C12N7/00 , A61K39/00 , C12N2740/16045 , C12N2740/16052 , C12N2810/10
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
Abstract translation: 使用用炔烃修饰的生物分子(例如脂肪酸,碳水化合物和脂质)标记的病毒的方法来治疗感染病毒的植物,昆虫或动物或增加病毒如人免疫缺陷病毒的感染性, 被提供。 还提供了用炔修饰的生物分子如脂肪酸,碳水化合物或类异戊二烯脂质来标记病毒(例如人类免疫缺陷病毒)的方法。 用炔烃修饰的生物分子标记的病毒可以与药学上可接受的赋形剂组合以产生药物组合物,任选地含有另一种抗病毒剂和/或递送剂,例如脂质体。
-
公开(公告)号:US10550422B2
公开(公告)日:2020-02-04
申请号:US15332304
申请日:2016-10-24
Inventor: Kyle R. Gee , Brian Agnew , Adrian Salic , Timothy J. Mitchison
IPC: C12Q1/6806 , C12Q1/68 , C12Q1/6816 , C12Q1/6841 , G01N33/50 , G01N33/58
Abstract: The present invention relates to methods for the labeling of nucleic acid polymers in vitro and in vivo. Certain methods are provided that include a [3+2] cycloaddition between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent attached to a label. Other methods are provided that include a Staudinger ligation between a nucleotide analogue incorporated into a nucleic acid polymer and a reagent comprising a substituted triarylphosphine attached to a label. Such methods do not require fixation and denaturation and therefore can be applied to the labeling of nucleic acid polymers in living cells and in organisms. Also provided are methods for measuring cellular proliferation. In these methods, the amount of label incorporated into the DNA is measured as an indication of cellular proliferation. The methods of the invention can be used in a wide variety of applications including clinical diagnosis of diseases and disorders in which cellular proliferation is involved, toxicity assays, and as a tool for the study of chromosomes' ultrastructures.
-
公开(公告)号:US20180201907A1
公开(公告)日:2018-07-19
申请号:US15920191
申请日:2018-03-13
Applicant: LIFE TECHNOLOGIES CORPORATION
Inventor: Brian Agnew
IPC: C12N7/00
CPC classification number: C12N7/00 , A61K39/00 , C12N2740/16045 , C12N2740/16052 , C12N2810/10
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
公开(公告)号:US09890361B2
公开(公告)日:2018-02-13
申请号:US14374404
申请日:2013-01-25
Inventor: Brian Agnew , David Graham
CPC classification number: C12N7/00 , A61K39/00 , A61K48/00 , C12N2740/16034 , C12N2740/16045 , C12N2740/16051 , C12N2810/10
Abstract: Methods of using viruses labeled with alkyne-modified biomolecules, such as fatty acids, carbohydrates and lipids, to treat a plant, an insect or an animal infected with a virus or to increase the infectivity of a virus, such as the human immunodeficiency virus, are provided. Also provided are methods of labeling a virus, such as human immunodeficiency virus, with an alkyne-modified biomolecule, such as a fatty acid, a carbohydrate, or an isoprenoid lipid. The viruses labeled with alkyne-modified biomolecules may be combined with a pharmaceutically acceptable excipient to produce a pharmaceutical composition, optionally containing another anti-viral agent and/or a delivery agent, such as a liposome.
-
-
-
-
-
-
-
-
-